March 6 (Reuters) - Novan Inc
* Novan provides update on SB204 development program
* Novan Inc - Intends to proceed with SB204 development program
* Novan Inc- Meeting could lead to a new drug application, or NDA, submission targeted in Q1 of 2018
* Novan Inc - Continues to believe that company’s cash on hand is sufficient to fund operations at least through end of 2017
* Novan - Intends to pursue pre-submission meeting with FDA, to discuss entirety of SB204 development program in Q3 of 2017
* Novan Inc - Anticipates that additional funding will be required to support SB204 through FDA process, as well as to fund operations beyond 2017 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.